BRNS vs EXPE · $38.2M cap vs P/E 20, rev $7.74B
Barinthus Biotherapeutics plc (BRNS) versus Expedia Group Inc. (EXPE) — a side-by-side from cached financials, not a winner call.
Barinthus Biotherapeutics plc (BRNS) is a biotechnology company listed on US.
Expedia Group Inc. (EXPE) is a travel services company listed on US.
Latest reported BRNS revenue for 2025-09-30 was $0. Net income was -$14.6M. BRNS currently screens at market cap $38.2M.
Latest reported EXPE revenue for 2026-06-30 was $7.74B. Net income was $872.0M. EXPE currently screens at market cap $21.71B and trailing P/E 20.4.
BRNS currently screens at market cap $38.2M. EXPE currently screens at market cap $21.71B and trailing P/E 20.4.
Not investment advice. Open the BRNS and EXPE stock pages for the full models.
Not investment advice.